The European Commission (EC) has granted exceptional marketing authorization for NEZGLYAL® (leriglitazone), marking the first pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD) in the EU. This therapy, aimed at male …
Organ Donation